The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Phase 2 Study of Lamivudine in Patients With p53 Mutant Metastatic Colorectal Cancer
Official Title: A Phase 2 Study of Lamivudine in Patients With p53 Mutant Metastatic Colorectal Cancer
Study ID: NCT03144804
Brief Summary: This research study is studying a drug as a possible treatment for p53 mutant metastatic colorectal cancer. The drug involved in this study is: -Lamivudine
Detailed Description: This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational drug to learn whether the drug works in treating a specific disease. "Investigational" means that the drug is being studied. The FDA (the U.S. Food and Drug Administration) has not approved lamivudine for this specific disease but it has been approved for other uses. In this research study, the investigators are studying the effects of lamivudine on this type of cancer. This drug may help prevent the growth and spread of the cancer cells to other parts of the body. The investigators have discovered that this particular type of colon cancer, which has a p53 mutation may be sensitive to treatment with lamivudine by impairing the ability of the cancer cells to grow.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Massachusetts general Hospital, Boston, Massachusetts, United States
Name: Aparna R. Parikh, MD
Affiliation: Massachusetts General Hospital
Role: PRINCIPAL_INVESTIGATOR